Cyclin-Dependent Kinases to Endocrine Therapy | Adding CDK46 inhibitors to Frontline or 2nd-Line Setting
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Cyclin-Dependent Kinases to Endocrine Therapy | Adding CDK-46 inhibitors to Frontline or 2nd-Line Setting at MOASC 2018.
Author: moasc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
The TAILORx study
Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means endocrine therapy alone is similar in efficacy to chemoendoc...
Author: obr
Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts
The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine Therapy
Hannah Linden, MD, University of Washington shares The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine Therapy at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers
Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
MONARCH 2: Abemaciclib with Fulvestrant in HR+/HER2-Positive Early Breast Cancer
Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib with fulvestrant in patients with HR+/HER2- Advanced Breast Cancer who have progressed on endocrine therapy....
Author: moasc
Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Who Should Get Genomic Profilers in Breast Cancer
Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains which patients should get endocrine therapy and genomic profiling in breast cancer. This was recorded at the 2017 Nati...
Author: NCCN2017
Added: 03/31/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 31, 2017 Category: Cancer & Oncology Source Type: podcasts
Endocrine Therapy in Breast Cancer: Best Bet on Duration
Dr Harold Burstein reviews the latest data on duration of adjuvant endocrine therapy in metastatic breast cancer, and provides much-needed recommendations on how to approach the topic with patients. (Source: Medscape Oncology)
Source: Medscape Oncology - December 19, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Extended endocrine therapy for the treatment and prevention of breast cancer relapse
Antonio Llombart, MD, PhD, of the University Hospital Arnau de Vilanova, Valencia, Spain, discusses extended endocrine therapy for the prevention of relapse of breast cancer at the 2016 World Congress...
Author: VJOncology
Added: 11/30/2016 (Source: Oncology Tube)
Source: Oncology Tube - November 30, 2016 Category: Cancer & Oncology Source Type: podcasts
Combination treatments for premenopausal breast cancer: endocrine therapy and ovarian suppression
Antonio Llombart, MD, PhD, of the University Hospital Arnau de Vilanova, Valencia, Spain, discusses new combination treatments for patients with breast cancer at the 2016 World Congress on Controversi...
Author: VJOncology
Added: 11/29/2016 (Source: Oncology Tube)
Source: Oncology Tube - November 29, 2016 Category: Cancer & Oncology Source Type: podcasts
JAMA Oncology : Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
Interview with Gretchen L. Gierach, PhD, author of Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - October 6, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer (JAMA Oncology)
Interview with Gretchen L. Gierach, PhD, author of Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - October 6, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Breast Cancer Index: How Does BCI Work?
Extend or End Endocrine Therapy After Year 5 for ER+ Breast Cancer Patients?<br /><br />Please visit <a target='_blank' href='http://www.breastcancerindex.com'>http://www.breastcancerinde...</a> for more information.<br />Facebook: <a target='_blank' href='http://www.facebook.com/answersbeyond5'>http://www.facebook.com/ans...</a><br />T...
Author: Breast Cancer Index
Added: 10/03/2016 (Source: Oncology Tube)
Source: Oncology Tube - October 3, 2016 Category: Cancer & Oncology Source Type: podcasts
Endocrine therapy in pregnant women with breast cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germ...
Author: EMJ
Added: 02/25/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 25, 2016 Category: Cancer & Oncology Source Type: podcasts
An Advance in Molecular Medicine to Manage Breast Cancer
In the era of molecular medicine, there is now a tool called Breast Cancer Index (BCI) to help physicians determine whether to recommend extended endocrine therapy.
Author: BreastCancerIndex
Added: 12/14/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 14, 2015 Category: Cancer & Oncology Source Type: podcasts
